

I hereby certify that this correspondence is being  
delivered by hand to:

Technology Center 1600  
Assistant Commissioner for Patents  
Washington, D.C. 20231

On 12/09/02

TOWNSEND and TOWNSEND and CREW LLP

By: MAI HAN VO

**PATENT**  
Attorney Docket No.: 015270-006444US  
Client Reference No.: 228-US-NEW2C4

**RECEIVED**

DEC 11 2002

TECH CENTER 1600/2900

RECEIVED  
TECH CENTER 1600/2900  
02 DEC -9 PM 1:57

#12/12/02  
12-17-02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

John P. Anderson et al.

Application No.: 09/724,571

Filed: November 28, 2000

For: BETA-SECRETASE ENZYME  
COMPOSITIONS AND METHODS

Examiner: Thaian N. Ton

Art Unit: 1632

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Technology Center 1600  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/471,669, filed December 24, 1999 (Attorney Docket No. 015270-006430US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Cite no. 78 is a copy of the International Search Report issued for the corresponding International application, PCT/US00/03819. Cite No. 65 is a copy of a press release announcing that Elan Corporation, plc and Pharmacia Corporation entered into a research collaboration focused on the discovery of small molecule inhibitors of beta-secretase for the

treatment of Alzheimer's disease. Elan Pharmaceuticals, Inc. assignee of the instant application, is affiliated with Elan Corporation, plc.

Applicants also cite commonly owned copending applications and issued patents directed to related subject matter:

08/480,498, filed 06/07/95, issuing as US Patent 5,744,346 on April 28, 1998;  
08/485,152, filed 06/07/95;  
08/659,984, filed 06/07/96, issuing as US Patent 5,942,400 on August 24, 1999;  
08/660,531, filed 06/07/96, issuing as US Patent 6,221,645 on April 24, 2001;  
09/054,334, filed 04/02/98, issuing as US Patent 6,329,163 on December 11, 2001;  
09/404,578, filed 09/23/99;  
09/471,669, filed 12/24/99;  
09/501,708, filed 02/10/00;  
09/723,722, filed 11/28/00;  
09/723,739, filed 11/28/00;  
09/724,568, filed 11/28/00;  
09/724,566, filed 11/28/00;  
09/724,569, filed 11/28/00;  
09/724,571, filed 11/28/00; and,  
10/099,922, filed 03/15/02;

Applicants further cite the following commonly owned abandoned applications directed to related subject matter:

60/114,408, filed 12/31/98;  
60/119,571, filed 02/10/99;  
60/139,172, filed 06/15/99;  
60/168,854, filed 12/02/99; and,  
09/730,329, filed 12/04/00.


As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference

should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in cursive script, reading "Rosemarie L. Celli".

Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC:rlc  
PA 3269358 v2